BDSA and Management Science Associates, Inc., announced a strategic alliance to revolutionize cannabis market insights. This collaboration marks a significant milestone in the industry, bringing together the expertise of both organizations to provide data collection, reporting and analytical capabilities to those participating or interested in the cannabis market.
BDSA and MSA will collaborate on various fronts, including offering industry cross-analysis between BDSA's clients focused on the cannabis industry and MSA's clients in the CPG, health care and government sectors, and providing in-depth technical support to clients with complex data requirements.
One of the key advantages of this collaboration is MSA's patented and HIPAA-compliant methodology for de-identifying protected health information. Combined with BDSA's comprehensive data, this methodology enables statistical analysis of consumers and delivers insights into the intersection of purchasing cannabis and pharmaceuticals for health care needs. According to the company for the first time, statistically significant cannabis consumption and real-world health care data will be combined to identify the impact of cannabis consumption on consumer health and purchasing.
“Our collaboration with MSA will revolutionize our clients' understanding of how cannabis addresses diverse consumer needs,” stated Roy Bingham, co-founder and CEO of BDSA. “With half the population having consumed cannabis in the past six months, this is no longer a niche category only of interest to those within the industry. This partnership will provide actionable, revenue-driving audience, sales impact and forecasting opportunities to companies inside and outside the cannabis industry.”
Stephen Gongaware, executive vice president of business development at MSA, stated: “We are excited to partner with BDSA to expand our data portfolio to include critical sales insights from cannabis dispensaries. This collaboration will benefit companies both inside and outside the cannabis industry, helping them navigate this rapidly evolving landscape. Our joint analysis across datasets will help size new audiences and revenue opportunities and our ongoing study will shed light on the impact of cannabis purchasing on pharma, tobacco and alcohol audiences, usage and purchasing.”
Photo: Benzinga edit with photos by geralt and lindsayfox on Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.